Long-term doxycycline-controlled expression of human tyrosine hydroxylase after direct adenovirus-mediated gene transfer to a rat model of Parkinson's disease.
about
Reversal of motor impairments in parkinsonian rats by continuous intrastriatal delivery of L-dopa using rAAV-mediated gene transferNonneurotropic adenovirus: a vector for gene transfer to the brain and gene therapy of neurological disordersCirculating anti-wild-type adeno-associated virus type 2 (AAV2) antibodies inhibit recombinant AAV2 (rAAV2)-mediated, but not rAAV5-mediated, gene transfer in the brain.Enhancement of cell-specific transgene expression from a Tet-Off regulatory system using a transcriptional amplification strategy in the rat brainViral-based modelling and correction of neurodegenerative diseases by RNA interference.Controlled Striatal DOPA Production From a Gene Delivery System in a Rodent Model of Parkinson's Disease.Design of a single AAV vector for coexpression of TH and GCH1 to establish continuous DOPA synthesis in a rat model of Parkinson's diseaseGene therapy for Parkinson's disease using recombinant adeno-associated viral vectors.Regulatable gene expression systems for gene therapy applications: progress and future challenges.Synaptic sprouting increases the uptake capacities of motoneurons in amyotrophic lateral sclerosis miceSubthalamic hGAD65 gene therapy and striatum TH gene transfer in a Parkinson's disease rat model.Correction of a rat model of Parkinson's disease by coexpression of tyrosine hydroxylase and aromatic amino acid decarboxylase from a helper virus-free herpes simplex virus type 1 vectorCoexpression of tyrosine hydroxylase, GTP cyclohydrolase I, aromatic amino acid decarboxylase, and vesicular monoamine transporter 2 from a helper virus-free herpes simplex virus type 1 vector supports high-level, long-term biochemical and behavioraContinuous DOPA synthesis from a single AAV: dosing and efficacy in models of Parkinson's disease.A next step in adeno-associated virus-mediated gene therapy for neurological diseases: regulation and targeting.Testing the therapeutic potential of doxycycline in a Drosophila melanogaster model of Alzheimer disease.The vesicular glutamate transporter-1 upstream promoter and first intron each support glutamatergic-specific expression in rat postrhinal cortex.Gene delivery to differentiated neurotypic cells with RGD and HIV Tat peptide functionalized polymeric nanoparticles.Viral gene delivery.Regulated and prolonged expression of mIFN(alpha) in immunocompetent mice mediated by a helper-dependent adenovirus vector.Evaluation of the tetracycline- and ecdysone-inducible systems for expression of neurotransmitter receptors in mammalian cells.Modulation of neuronal survival and axonal growth in vivo by tetracycline-regulated neurotrophin expression.Gene therapy for dopamine replacement in Parkinson's disease.Long-term inducible expression in striatal neurons from helper virus-free HSV-1 vectors that contain the tetracycline-inducible promoter system.Rat marrow stromal cells rapidly transduced with a self-inactivating retrovirus synthesize L-DOPA in vitro.Highly suppressible expression of single-chain interleukin-12 by doxycycline following adenoviral infection with a single-vector Tet-regulatory system.Brain targeted oral delivery of doxycycline hydrochloride encapsulated Tween 80 coated chitosan nanoparticles against ketamine induced psychosis: behavioral, biochemical, neurochemical and histological alterations in mice.
P2860
Q31045537-3AD311E3-A2A5-450E-BF8E-9251474BFC62Q33985663-30619B89-1630-410A-8FA4-CBA7FC5A7A28Q34193457-8430DBE7-7852-42BC-AB14-84E412D1745BQ34233867-4FF3B2CA-3D85-49F5-A03A-21821249F6BFQ34471754-09052D92-6FF1-4F59-91A9-289B3F4D4637Q35582092-FC6D24C3-CF58-4FF7-8829-8C5AFE9BA877Q36085361-578FFD0B-DEA4-40C5-8B04-FEBA0AC6D9D3Q36150495-6AAFA99E-33BC-44D1-961C-D520FC24D114Q36157542-44848B4A-D7F7-4E6B-96AD-031F5B7AE910Q36316660-B92309D0-1786-4F3F-818F-9E38B02BCDEAQ36853737-0661FA1C-DF2F-4AB4-A187-EAD0EF410EC1Q36969304-DFC0BDD6-4F33-4123-A8EC-56E5D092D050Q36969314-B0C7B521-30EA-4455-8B89-027103ACA4F5Q36989384-A30BCCCD-15DD-4CD3-B5A7-C6ED693A4020Q38075068-19D4BDDA-85D7-4475-BB7E-EB2ACCAF8869Q39458294-BA888BC5-AE6F-4393-BF6F-4439A3B4BF4DQ39617892-2189B2DA-AF11-44BF-90AF-63C9943A24CCQ40268859-B182B134-4402-4540-BC35-CDE6D0278D83Q40732042-A80F39BA-8212-4004-8517-106FD541BCFBQ40753328-E9AE3AB8-82DD-45AF-BDB7-5FDC2A02BB4DQ40775660-3887C39B-A404-4E5A-8F8A-AA624F344C14Q42506402-AC37CD0C-1577-4286-8A06-E665271B7D69Q43109283-64F921CB-415C-402E-A545-E9B63C25E6C8Q43244057-8CC3AD58-9AFC-4B84-A41B-7FFC2F0FD5BFQ43710410-5C85B94E-74E5-4B5E-ABBD-2F6DE17DA594Q44383524-6D1AC7C7-F5DF-476A-876E-35997973BAB6Q47248889-95BB3947-1685-4A21-9F99-0F5FAEACDAEB
P2860
Long-term doxycycline-controlled expression of human tyrosine hydroxylase after direct adenovirus-mediated gene transfer to a rat model of Parkinson's disease.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
1999年论文
@zh
1999年论文
@zh-cn
name
Long-term doxycycline-controll ...... model of Parkinson's disease.
@ast
Long-term doxycycline-controll ...... model of Parkinson's disease.
@en
type
label
Long-term doxycycline-controll ...... model of Parkinson's disease.
@ast
Long-term doxycycline-controll ...... model of Parkinson's disease.
@en
prefLabel
Long-term doxycycline-controll ...... model of Parkinson's disease.
@ast
Long-term doxycycline-controll ...... model of Parkinson's disease.
@en
P2093
P2860
P356
P1476
Long-term doxycycline-controll ...... t model of Parkinson's disease
@en
P2093
P2860
P304
12120-12125
P356
10.1073/PNAS.96.21.12120
P407
P50
P577
1999-10-01T00:00:00Z